chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Symptoms began getting worse within the week after October 8. Including: Leaning down to put down a box, I had to sit down, heart was pounding, needle pain in chest. I would be walking outside and all of a sudden my heart began to race, felt very hot and began sweating. Pins and needles and ache in my chest. Ants and pins all over my body, especially in left leg (which began feeling heavy and going numb if I walked more than about 30min). Constantly feeling like someone was sitting on my chest, hard time taking a full breathe because of it. Feeling completely wiped out, exhausted and out of breathe from doing something simple as going to grocery store, or going under the table to reach down for something. Heart pounding one second, then feeling like I have a faint heart beat the next, and needing to sit down because light headed. My heart going completely out of rhythm on a simple walk outside, that I felt a pulse in my ears and had to hold onto something because I couldn't catch a breathe or my grounding. Fingers swelling after taking a walk outside, hard to close hands to make a fist. Left arm went numb, tingling and feeling very heavy on October 15th, which was the first day I managed to find strength to leave the house because I had a cardiologist appt.
Vaccine administered at about 13:00 on 12/29/20. Within 5 minutes, patient developed became flushed and developed tachycardia as high as 160, and a feeling of being "overstimulated". The patient self-administered 10 mg Claritin. Within 20 minutes of injection, the patient developed profuse diarrhea and erythematous modeling around the injection side. In the evening, she had fatigue body aches, and nausea. The following morning, it was clear that the patient had an injection site reaction with firmness, redness, and warmth. The erythematous modeling had spread to the wrist of the left arm as well as to the chest and down to the elbow on the right arm. No rash on rash or any other sign of allergy or anaphylaxis.
Information has been received from a physician referring to unspecified patients of unknown age and gender. Information about medical history and concurrent conditions were unspecified. On unknown dates, the patients were vaccinated with improperly stored VARIVAX (Merck) (lot # L001327, expiration date 13-JAN-2017, dose and route were unknown). The VARIVAX (Merck) was stored under -11.8 F for 47 hours and 3 minutes. There was no previous temperature excursion. It was called because of a "data logger". No adverse effect reported. This is one of two reports received from the same source. Additional information has been requested.
Pt initially reported an itchy throat which later progressed to dysphagia and sensation of her throat closiing.  She developed a cough.  Epi adminiistered to minimal improvement.  Paramedics on site.  IV solumedrol and benadryl given via IV.  Pt reported improvement in her symptoms after a few minutes.  She was taken to NYU.
I felt sick and fatigue after getting the shot. And the next morning I passed out on my way to work and wrecked my truck.
Felt like she was breathing fire, flushing, pain ran up left arm to neck, clavicle, joint pain muscle ache, chill, fatigue, swelling under left armpit. Tingling to the face, ringing in ears from covid got worse, neuropathy real intense.
had the flu symptoms on vaccine 2; was out for about 4 days on vaccine 2; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (had the flu symptoms on vaccine 2) and VACCINATION COMPLICATION (was out for about 4 days on vaccine 2) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination.     The patient's past medical history included Artery dissection (dissected celiac artery) in 2020 and Cardiac arrest (9 years ago she experienced heart attack). Concurrent medical conditions included Heart disease, unspecified.    On 07-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA (had the flu symptoms on vaccine 2) and VACCINATION COMPLICATION (was out for about 4 days on vaccine 2). At the time of the report, INFLUENZA (had the flu symptoms on vaccine 2) and VACCINATION COMPLICATION (was out for about 4 days on vaccine 2) outcome was unknown.            Concomitant medicine included heart medications No treatment information were reported by the reporter   This case was linked to MOD-2021-377079, MOD-2021-378958 (Patient Link).
felt like his lungs were burning; This case was reported by a physician via sales rep and described the occurrence of lung irritation in a 54-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced lung irritation. On an unknown date, the outcome of the lung irritation was unknown.   It was unknown if the reporter considered the lung irritation to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix vaccine and he felt like his lungs was burning. No other information was reported.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR136715:Same reporter
13 mo. old M who developed urticarial lesions after immunizations given. 8/18/15 mom notices non pruritic lesions on face and arms approx 10:30 last evening. Mom gave BENADRYL lotion no shortness of breath or swelling.
cramps; abdominal pains; Weak with low energy; Severe watery diarrhea; nausea; vomiting; This is a spontaneous report from a contactable physician (Patient). A 42-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: el3248) via an unspecified route of administration, administered in Arm Right on 22Jan2021 22:00 (Age at Vaccination 42-years-old) as single dose for COVID-19 immunization. Medical history included gastrooesophageal reflux disease (GERD) from 22Jan2021 to an unknown date. Patient had known allergies sensitive to doxy. Concomitant medication was not provided. No other vaccine in four weeks. other medications in two weeks Protonix; 7ketosteroidDHEA. No covid prior vaccination and no covid tested post vaccination. Previously patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: ek5730) via intramuscular route of administration, administered in Arm left on 04Jan2021 10:00 AM as single dose for COVID-19 immunization. On 22Jan2021 the patient experienced abdominal pains, weak with low energy, severe watery diarrhea, nausea and vomiting. On an unspecified date patient experienced cramp. It was reported that abdominal pains and cramps starting about 12 hours after injection. Weak with low energy. Severe watery diarrhea along with nausea and vomiting. Symptoms lasted 72 hours then completely resolved. Patient received treatment of IV fluids, zofran, phenergan and pepcid. The outcome of the events was in 2021.while outcome of cramps was unknown.  Follow-up attempts are completed. No further information is expected.
This spontaneous report as received from a healthcare worker refers to a patient of unknown age and gender. On 14-JAN-2015 the patient was vaccinated with VARIVAX (Merck) 0.5 ml, subcutaneously (lot # H020251, expiry date 08-NOV-2014) (dosing regimen and frequency unknown) for an unknown indication that had expired on 08-NOV-2014. No concomitant medications were reported. No adverse events were reported. The action taken with the therapy with VARIVAX (Merck) was unknown. The outcome of the events was unknown. The relatedness of the events to the therapy with VARIVAX (Merck) was unknown. No product quality issue was reported. Additional information has been requested.
Initial unsolicited report received from a nurse 5 August 2015. A 14-year-old male patient, concomitant medications was not reported, had received a dose of IMOVAX RABIES (batch number, expiry date, route and site of administration were not reported) on 27 July 2015 and continued post exposure series and received Imovax on day 7 of the series 31 July 2015. Patient also received a first dose of IMMUNOGLOBULIN HUMAN ANTIRABIES (HRIG) (batch number, expiry date, route and site of administration were not reported) 24 July 2015 and first dose of RABAVERT (batch number 556011A, expiry date, route and site of administration were not reported) intramuscularly on 24 July 2015. Illness at the time of vaccination was sinus, cold symptoms and feeling tired. Reported denies the patient pre-existing physician diagnosed allergies, birth defects, medical conditions. On 27 July 2015, i.e. same day after vaccination patient had experienced feeling fatigue and loss of energy. It was reported that, patient had required emergency room (ER). It was reported that patient was evaluated by physician who informed that not vaccine related and ordered blood work to determine cause of patient's symptoms and corrective treatments was not reported. At the time of this report, outcome of event was unknown. Documents held by sender: none. Follow up information received from a nurse on 3 September 2015. Patient had received 1 ml of Imovax rabies (lot number K1613) intramuscularly in left deltoid. Lab data included white blood cell (wbc) count 7.5 K/ul, red blood cell (rbc) count 5.22 m/ul, hemoglobin g/dl 14.5, hematocrit 44.1 percent, MCV 85 fl, MCH 27.8 pg, mchc 32.9 g/dl, rdw (Red cell distribution width) 12.1 percent, platelet count 372 k/ul, diff type automated, neutrophil 59 percent, lymphocytes 30, monocytes 8 percent, eosinophils 3 percent, basophils 0 percent, abs. neutrophils 4.4 k/ul, abs. lymphocyte 2.2 k/ul, Abs, monocytes 0.6 percent, abs. eosinophils 0.2 k/ul, abs. basophils 0.0 k/ul, Free T4: 1.23 NG/DL and Free T4: 1.23 NG/DL. Follow up report received from a nurse on 27 October 2015. It was reported that medical history, other medications, pre-existing physician diagnosed allergies, birth defects and medical conditions were none. The patient had received Rabies vaccine, day 14 on 5 August 2015. On 24 July 2015 patient went in emergency room for HRIG and rabies vaccine. On 15 August 2015 patient was recovered from the mentioned events. List of documents held by sender: none.
tongue felt numb, and then started to swell as well as throat.  Felt very weird swallowing.  Pharmacist gave me benedryl and made me stay there longer.
This spontaneous report as received from a consumer, who was the patient's father, refers to a 2 year old female patient. No information regarding the patient's medical history or concurrent conditions was provided. On an unknown date, the patient was vaccinated in error with a dose of ZOSTAVAX (dose and frequency reported as 1 injection, once; strength, route of administration, lot# and expiry date were not reported). There were no concomitant therapies reported. On an unknown date, the patient experienced fever, was throwing up and "felt stiff". The patient sought medical attention (spoke with an unspecified medical professional on an unspecified date). The outcome of the events was reported as not recovered. There was no product quality complaint (PQC) involved. The relatedness between ZOSTAVAX and the events was not provided. Additional information is not expected as no contact details were provided.
This spontaneous report was received from a registered nurse, and refers to a 21 year old patient of unknown gender. No information about the patient's medical history, concurrent conditions, concomitant medications and drug reactions/allergies was provided. On 04-OCT-2017, the patient was vaccinated with the first dose of GARDASIL 9, intramuscular route of administration, for prophylaxis, (strength, dose, frequency, lot number and expiration date were not provided). On 24-JAN-2018, the patient was vaccinated with the second dose of GARDASIL 9, intramuscular route of administration, for prophylaxis, (strength, dose, frequency, lot number and expiration date were not provided) and on 13-APR-2018, the patient was vaccinated with the third dose of GARDASIL 9, intramuscular route of administration, for prophylaxis, (strength, dose, frequency, lot number and expiration date were not provided). No adverse effects were reported.
Information has been received from a Registered Pharmacist (R.Ph.) concerning an approximately 69 year old female with no drug reaction/allergy who in approximately 2005 (4-5 years ago) was vaccinated with a dose of ZOSTAVAX (Merck). There was no concomitant medication. In 2009 the patient developed shingles. It was unspecified if the patient sought medical attention. At the time of this report, the outcome was unknown. Additional information has been requested.
Information has been received from a physician concerning a 22 year old female with allergic reaction to CECLOR, tetracycline, penicillin and sulfa who on 09-AUG-2007 was vaccinated with the first dose of GARDASIL (0.5ml, IM), the second dose (0.5ml, IM) was on 06-DEC-2007 and the date of third dose (0.5ml, IM) was unknown. Concomitant therapy included unspecified "birth control" medication. In July 2010 PAP results indicated the patient had high risk HPV. The patient had a colposcopy and biopsy and the results that showed high dysplasia and severe dysplasia. The patient's results showed "precancerous". the patient had routine office visit and would have surgery in the office. The patient had not recovered at time of report. High risk HPV and precancerous dysplasia were considered to be other important medical event. Additional information has been requested.
This spontaneous report was received from a pharmacist refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history, drug reactions and allergies were not reported. The patient's concomitant medication was reported as sterile diluent. On 19-FEB-2018, the patient was vaccinated with expired dose of VARIVAX (dose, units and frequency not reported) (lot # M004328 and expiration date: 26-JAN-2018) subcutaneously. No adverse effects and no additional information was provided. No product quality complaint was involved. Follow-up information was received from a registered nurse on 01-MAR-2018. The reporter confirmed that the patient did not experience any redness, swelling or fever and that the medication error happened during the dispensing and administration processes. Additionally, the reporter stated that the adverse events were previously reported to the doctor as well as the manufacturer and reported the expiration date for VARIVAX as 24-JAN-2018 with no digital data logger involved.
Patient has not reported any additional adverse experiences as a result.; a patient was accidentally given a fourth dose of HPV (Confirmed as GARDASIL 9).; This spontaneous report was received from a physician assistant, referring to a 17-year-old male patient. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant medications were not reported.   On 09-APR-2021, 8 months after his series was completed and the third dose administered, the patient was accidentally given a fourth dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) as prophylaxis (strength, route of administration, and anatomical location was not reported; lot number 1687291 has been verified to be a valid lot number for hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) prefilled syringe, expiration date reported and upon internal validation established as 11-SEP-2022) (extra dose administered). The patient had not reported any additional adverse experiences as a result. The reporter stated the patient received the complete 3 dose hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) vaccine series on time according to his age of 15 at the time of his first dose. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1687291; expirationdate: 11-SEP-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
Migraine, nausea,  fatigue.  Treatment: Ibuprofen, exedrine migraine, imitrex. Migraine continues 8 hours.
From initial information received on 15Feb05 from a RN regarding an adverse event occurring, it was reported that a 53 year old female pt received a dose of Ipol, lot number X1189, administered SC in the left arm and a dose of Tetanus and Diphtheria toxoids, lot number Td107, administered IM in the left arm on 03Feb05. The lot number provided for the Ipol product does no match that of a known manf product. Three days later, on 06Feb05, the pt developed pain and soreness in her left arm upon movement. The pt also c/o arm pain at night during sleep. Per the reporter, the pain and soreness still persist and the pt has not recovered from these events.
No additional AE reported; temperature excursion of 47.9 F for 47 min on Dec 1st 2022; This spontaneous report was received from a certified medical assistant and refers to a 7-month-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 19-DEC-2022, the patient was vaccinated with the third dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, lot #1892784, expiration date: 03-DEC-2023, administered orally for prophylaxis (strength and exact dose were not provided).  The vaccine underwent temperature excursion of 47.9 degrees Fahrenheit for 47 min (incorrect product storage) in clinical Practice on 01-DEC-2022. Data Logger was involved. No additional adverse event (AE) was reported. There was no product quality complaint (PQC).
No adverse effects noted or reported. No symptoms reported or noted by patient/client. Shingrix vaccine was given early. 2nd dose of vaccine was given at 3 wks. Shingrix is vaccine that is a series of 2 vaccines. 1st dose of vaccine was given 3/13/23 and 2nd dose was given 4/3/23. (Shingrix vaccine).
For the past month, my shoulder has experienced pain, especially when lifting anything or moving arm (like putting on a jacket). Wakes me up at night, especially if I roll over on my left arm.  Pain was noticable almost immediately after injection.  Nothing like this has EVER been experienced before and there was no physical activity or other explanation for this pain.  A month later, this pain is still present and not improving.
SWEATING, NAUSEA, VOMITING, DIZZINESS, FLUSHING APPROXIMATELY 32 HOURS AFTER INJECTION
Patient said that the immunizations were very painful when being injected subcutaneously and uncomfortable for many days. When in on 9/16/2015 the arm appeared normal and patint said there was no more pain.
Narrative:  Patient received three Pfizer vaccine doses at a non-agency facility. Dose #1 was administered 1/21/2021. Dose #2 was administered 2/15/2021. Dose #3 was administered 10/7/2021. Patient presented to the ED on 10/24/2021 with a chief complaint of nausea, diarrhea, and dry-heaving. He was also noted to be in atrial fibrillation with RVR. He was admitted to ICU due to need for diltiazem drip. He was given remdesivir, but developed bradycardia. Remdesivir was discontinued. Dexamethasone was initiated and was discontinued on 10/27/2021 due to stability on room air. He was discharged home from the hospital on 10/28/2021.
a little sore; felt a little bad; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (a little sore) and FEELING ABNORMAL (felt a little bad) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025B21A and 008B212A) for COVID-19 vaccination.     Concomitant products included SALBUTAMOL (ALBUTEROL HFA), BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT), LEVOCETIRIZINE, CYCLOBENZAPRINE, ATORVASTATIN, MONTELUKAST, MELOXICAM and DOCUSATE SODIUM (STOOL SOFTENER) for an unknown indication.   On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Apr-2021, the patient experienced MYALGIA (a little sore) and FEELING ABNORMAL (felt a little bad). At the time of the report, MYALGIA (a little sore) and FEELING ABNORMAL (felt a little bad) outcome was unknown. Not Provided          This case was linked to MOD-2021-110260 (Patient Link).
usual swelling of arm, fever, sweats , but added heart palpatations for about an hour or so 5 days after intermitt irregular heart beat    , swelling of lymph nodes- 5 days after starting to come down , and left breast - 5 day after swelling coming down but sore under arm
Pfizer Covid Vaccine given to an 11 y.o. & 7 month old child, after mother and child stated that he was 12 y.o.  Calculated DOB after injection given and realized that child was not 12 y.o.   No adverse reactions.
rash began 14MAR98 evening on inner aspect of rt arm, trunk, legs, neck;has had fever (oral of 100) since Sunday;c/o frontal h/a which migrated to back of head on rt side;c/o fatigue since Sunday;rash is maculopapular erythematous, pruritus
Subjective fever and headache < 1 hour after vaccine administration; muscle ache at the vaccine site (R arm) radiating to the R elbow and chest ~ 8 hours after administration. Level of pain and the fact that the symptoms were significantly worse than those that occurred on previous administrations of the vaccine (this is the 8th time Pt has received the anthrax vaccine) prompted an ED visit the following morning. Patient discharged with return precautions and analgesia.
Patient states that after the influenza vaccination she experienced prolonged illness, fatigue, malaise, fevers, chills, muscle weakness, inability to get out of bed. This lasted approximately 4 weeks. Patient states that she has been getting flu shots for 30 years and has never had a reaction .
WRONG DOSE OF VACCINE GIVEN ON 4/25/23.  PT RECEIVED BIVALENT BOOSTER DOSE 10MCG DOSE INSTEAD OF 25MCG DOSE .  NO ADVERSE VACCINE REACTIONS.
This spontaneous report as received from a certified medical assistant, via a company representative, refers to 16 patients of unknown age and genders. No information on their medical history, concurrent conditions or concomitant drugs was provided. On an unknown dates in 2014, reportedly between 01-MAY-2014 and 01-JUL-2014, the patients were vaccinated with VAQTA which was improperly stored (doses, administration sites and routes, lot # and expiration dates were not reported). This is one of several reports from the same reporter. Additional information has been requested.
On Oct 26th, 2004, pt received anthrax vaccine #6 SC along with Hep B IM in her left deltoid region. On Oct27th, 2004 pt noted redness, tenderness, pruritus and swelling surrounding vaccine site(s). Area increased in size by AM of 10/28/04, has had similar reactions with previous anthrax vaccines. Also on 10/28/04 noted small, round area of individual pruritic papules; has never experienced similar lesions and has not noted papules anywhere else on her body.
Extreme difficulty when breathing, consistent coughing, massive mucous production, low oxygen levels, severe congestion, Pneumonia, loss of appetite, sore throat, inflamed nasal passageways, inability to ambulate without overexhaustion and difficulty breathing